The information on this site is designed for patients. If you are a healthcare
professional,
click here.
*
NeuroStar TMS Therapy® is indicated for the treatment of Major Depressive
Disorder in adult patients who have failed to achieve satisfactory improvement from
one prior antidepressant medication at or above the minimal effective dose and duration
in the current episode.
|
|
|
Clinical trials have proven the safety of NeuroStar TMS Therapy®
in treating patients who've had an inadequate response to prior antidepressant medications.
Treatment with NeuroStar TMS Therapy caused very few side effects and was generally
well tolerated by patients. The most common side effect reported during clinical
trials was scalp discomfort—generally mild to moderate and occurring less frequently
after the first week of treatment.
Fewer than 5% of patients discontinued treatment with NeuroStar TMS Therapy due
to adverse events.
Over 10,000 active treatments were performed across all NeuroStar® clinical
trials demonstrating its safety1
- No seizures
- No systemic side effects
- No weight gain
- No sexual dysfunction
- No sedation
- No nausea
- No dry mouth
- No adverse effects on concentration or memory
- No device-drug interactions
NeuroStar TMS Therapy should not be used (is contraindicated) in patients with implanted
metallic devices or non-removable metallic objects in or around the head. NeuroStar
TMS Therapy should not be used in patients with implants controlled by physiological
signals. This includes pacemakers, implantable cardioverter defibrillators (ICDs),
and vagus nerve stimulators (VNS).
Learn about a typical NeuroStar TMS Therapy treatment session.
References:
- Janicak P, et al. Transcranial Magnetic Stimulation (TMS) in the Treatment of Major
Depression: A Comprehensive Summary of Safety Experience from Acute Exposure, Extended
Exposure and During Reintroduction Treatment. Journal of Clinical Psychiatry,
February 2008.
|
|